Free Trial
NASDAQ:CARA

Cara Therapeutics (CARA) Stock Price, News & Analysis

Cara Therapeutics logo

About Cara Therapeutics Stock (NASDAQ:CARA)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$13.29
$17.10
52-Week Range
N/A
Volume
237,144 shs
Average Volume
24,626 shs
Market Capitalization
$24.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00
Consensus Rating
Hold

Company Overview

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Cara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

CARA MarketRank™: 

Cara Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 793rd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cara Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cara Therapeutics has received no research coverage in the past 90 days.

  • Read more about Cara Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cara Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cara Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for CARA.
  • Dividend Yield

    Cara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cara Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CARA.
    • Insider Buying vs. Insider Selling

      In the past three months, Cara Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 3.10% of the stock of Cara Therapeutics is held by insiders.

    • Percentage Held by Institutions

      44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Cara Therapeutics' insider trading history.
    Receive CARA Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    CARA Stock News Headlines

    White House to reset Social Security?
    Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
    Cara Therapeutics board approves 1-for-3 reverse stock split
    See More Headlines

    CARA Stock Analysis - Frequently Asked Questions

    Cara Therapeutics, Inc. (NASDAQ:CARA) issued its earnings results on Wednesday, August, 14th. The biopharmaceutical company reported ($13.32) earnings per share for the quarter, missing the consensus estimate of ($9.72) by $3.60. The biopharmaceutical company earned $0.99 million during the quarter, compared to analysts' expectations of $1.26 million. Cara Therapeutics had a negative net margin of 1,099.76% and a negative trailing twelve-month return on equity of 367.97%.

    Shares of Cara Therapeutics reverse split on the morning of Wednesday, April 16th 2025. The 1-3 reverse split was announced on Monday, April 14th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

    Top institutional shareholders of Cara Therapeutics include Simplex Trading LLC. Insiders that own company stock include Christopher Posner, Frederique PhD Menzaghi, Scott Terrillion, Joana Goncalves, Martin Vogelbaum and Jeffrey L Ives.
    View institutional ownership trends
    .

    Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Cara Therapeutics investors own include LIONS GATE ENTERTAINMENT CORP /CN/ (LGF.A), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), First Solar (FSLR) and Tesla (TSLA).

    Company Calendar

    Last Earnings
    8/14/2024
    Today
    5/30/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:CARA
    Employees
    80
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $36.00
    High Stock Price Target
    $36.00
    Low Stock Price Target
    $36.00
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.00
    Research Coverage
    5 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$118.51 million
    Net Margins
    -1,099.76%
    Pretax Margin
    -1,099.76%

    Debt

    Sales & Book Value

    Annual Sales
    $7.14 million
    Price / Cash Flow
    N/A
    Book Value
    $12.58 per share
    Price / Book
    N/A

    Miscellaneous

    Free Float
    4,429,000
    Market Cap
    $24.33 million
    Optionable
    Optionable
    Beta
    0.41

    Social Links

    Ten Starter Stocks For Beginners to Buy Now Cover

    Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

    Get This Free Report

    This page (NASDAQ:CARA) was last updated on 5/31/2025 by MarketBeat.com Staff
    From Our Partners